Drug Approval | January 08, 2026
Rapid-acting ADHD treatment Azstarys now approved in China
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Subscribe To Our Newsletter & Stay Updated
